A Study of AC-101 Tablets in Participants With Moderate to Severe Active Ulcerative Colitis

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

China

The First Affiliated Hospital,Sun Yat-sen University, Guangzhou, Guangdong